2-[3-chloro-4-[5-(trifluoromethyl)tetrazol-1-yl]phenyl]-3-cyclohexyl-N-(1,3-thiazol-2-yl)prop-2-enamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-[3-chloro-4-[5-(trifluoromethyl)tetrazol-1-yl]phenyl]-3-cyclohexyl-N-(1,3-thiazol-2-yl)prop-2-enamide
• 化学式: C₂₀H₁₈ClF₃N₆OS
• 分子量: 482.9
• InChiKey: QIMSMHHSGVQCCP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  114
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• Tetrazolyl-phenyl acetamide glucokinase activators
  申请人：——

  公开号：US20020035266A1

  公开（公告）日：2002-03-21

  Tetrazolyl-phenyl acetamides are active as glucokinase activators, and are able to increase insulin secretion, which makes them useful for treating type II diabetes.

  四唑基苯乙酰胺作为葡萄糖激酶激活剂具有活性，能够增加胰岛素分泌，因此对治疗2型糖尿病有用。
• Tetrazolyl-phenyl actamide glucokinase activators
  申请人：——

  公开号：US20020065275A1

  公开（公告）日：2002-05-30

  Tetrazolyl-phenyl acetamides are active as glucokinase activators, and are able to increase insulin secretion, which makes them useful for treating type II diabetes.

  Tetrazolyl-phenyl 醋酸酰胺具有活性，能够激活葡萄糖激酶，增加胰岛素分泌，因此对治疗II型糖尿病有用。
• TETRAZOLYL-PHENYL ACETAMIDE GLUCOKINASE ACTIVATORS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1311504B1

  公开（公告）日：2005-06-15
• TREATMENT OF LIVER DISEASE
  申请人：UNIVERSITY OF NEWCASTLE UPON TYNE

  公开号：US20200188394A1

  公开（公告）日：2020-06-18

  Aspects and embodiments of the present invention relate to the treatment of fatty liver diseases such as for example, Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). Particularly, but not exclusively certain embodiments relate to activators of glucokinase (GKAs) for use in the treatment of these fatty liver diseases. Also included in the present invention are inter alia pharmaceutical compositions comprising the GKAs, together with methods of treating such disorders as well as other subject matter.
• US6369232B1
  申请人：——

  公开号：US6369232B1

  公开（公告）日：2002-04-09